Arexvy has been approved in Malaysia for RSV (respiratory syncytial virus), for older adults aged 60 and above. The vaccine ...
GlobalData on MSN1d
Vicebio secures $100m to advance RSV and hMPV vaccine combo to Phase IUK-based startup Vicebio has raised $100m to advance its “next-generation vaccines” for respiratory illnesses, including ...
GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced that the Arexvy vaccine (MAL24086007ARZ) has been approved in Malaysia for respiratory syncytial virus (RSV). RSV is a common respiratory ...
Zacks.com on MSN5d
GSK Meets Study Goal for Co-Administered RSV-Shingles VaccinesGSK plc GSK announced positive topline results from a phase III study evaluating the co-administration of its two marketed ...
Respiratory syncytial virus, or RSV, season is just a few months away, but new vaccine options have already arrived for ...
Results looking at the first season of RSV use shows that it is 75% effective at preventing RSV-associated hospitalizations ...
GSK touts co-administration data for RSV, shingles vaccines as narrowed CDC guidance threatens sales
In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses ...
GSK released data from a Phase 3 trial evaluating the co-administration of Arexvy and Shingrix vaccines in adults 50+. The ...
Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.
Respiratory syncytial virus (RSV) vaccination in adults aged 60 years and older may be cost-effective in preventing illness, ...
If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...
The FDA in June expanded the use of GSK's Arexvy vaccine in adults between the ages of 50 and 59. The U.S. Centers for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback